血清胆碱酯酶对脓毒性休克预后的价值
该研究纳入郑州大学第一附属医院2013年6月至2017年6月收治的脓毒性休克患者,最终356例完成随访,28天死亡率为60.1%(214/356),2年死亡率为67.4%(240/356)。多因素Cox回归显示年龄(RR=1.444)、APACHE II评分(RR=2.249)、SChE(RR=1.469)和乳酸(RR=2.190)是28天死亡的独立危险因素。SChE单独预测28天预后的AUC为0.574,预测价值较弱;SChE联合APACHE II评分和乳酸预测的AUC为0.807,优于APACHE II评分(0.785)或乳酸(0.697)单独预测,敏感度79.9%,特异度68.5%。低SChE组(≤4000 U/L)28天死亡率显著高于正常SChE组(63.1% vs 51.1%,P<0.05),但ICU死亡率、2年死亡率和ICU住院时间两组无统计学差异。
要点
- 脓毒性休克患者SChE≤4000 U/L时28天死亡率为63.1%(169/268),高于SChE>4000 U/L组的51.1%(45/88),差异有统计学意义(P<0.05)。
- SChE是脓毒性休克患者28天死亡的独立危险因素(RR=1.469,95%CI 1.057-2.043,P=0.022)。
- SChE单独预测28天预后的AUC为0.574,预测价值较弱;SChE联合APACHE II评分和乳酸预测的AUC为0.807,敏感度79.9%,特异度68.5%。
- 低SChE组与正常SChE组的ICU死亡率、2年死亡率和ICU住院时间无统计学差异(均P>0.05)。
- Kaplan-Meier分析显示低SChE组无终点事件累积生存率显著低于正常SChE组(Log-Rank检验:χ2=5.852,P=0.016)。
适用人群与场景
- 2013年6月至2017年6月郑州大学第一附属医院收治的脓毒性休克患者,按纳入和排除标准最终纳入385例,成功随访356例。
诊断标准与关键阈值
- 按SChE水平分组:低SChE组为SChE≤4000 U/L(n=268),正常SChE组为SChE>4000 U/L(n=88)。
研究设计与关键结果
- 研究类型为队列研究,纳入356例脓毒性休克患者,28天死亡214例(60.1%),2年死亡240例(67.4%)。
- 28天死亡组较生存组年龄更大、APACHE II评分更高、部分肝肾功能指标更高、乳酸更高,而白细胞计数、血小板计数和SChE更低,差异均有统计学意义。
- 多因素Cox回归显示年龄(RR=1.444,95%CI 1.090-1.914,P=0.010)、APACHE II评分(RR=2.249,95%CI 1.688-2.997,P=0.000)、SChE(RR=1.469,95%CI 1.057-2.043,P=0.022)和乳酸(RR=2.190,95%CI 1.636-2.931,P=0.000)是28天死亡的独立危险因素。
- ROC曲线显示SChE预测28天预后的AUC为0.574;SChE联合APACHE II评分和乳酸预测的AUC为0.807,优于APACHE II评分(0.785)或乳酸(0.697)单独预测,敏感度79.9%,特异度68.5%。
- 低SChE组28天死亡率为63.1%(169/268),高于正常SChE组的51.1%(45/88),差异有统计学意义(P<0.05);两组ICU死亡率[59.7%(160/268) vs 48.9%(43/88)]、2年死亡率[69.8%(187/268) vs 60.2%(53/88)]和ICU住院时间[4(2,7)天 vs 5(2,9)天]均无统计学差异(均P>0.05)。
- Kaplan-Meier生存曲线显示低SChE组无终点事件累积生存率显著低于正常SChE组(Log-Rank检验:χ2=5.852,P=0.016)。
证据类型、等级与局限
- 证据类型为队列研究,原文未报告证据等级或推荐强度。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为SChE低于正常的脓毒性休克患者28天死亡风险增加,SChE水平是28天死亡的独立危险因素,是评估脓毒性休克患者短期预后的指标之一。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the relationship between serum cholinesterase (SChE) level and the prognosis of patients with septic shock (SS).
METHODS: A total of 594 patients with SS admitted to the First Affiliated Hospital of Zhengzhou University from June 2013 to June 2017 were enrolled. General data such as gender, age, acute physiology and chronic health evaluation II (APACHE II) score were recorded as well as routine blood test, procalcitonin (PCT), hepatic function, renal function, coagulation function and blood gas analysis parameters within 48 hours of SS diagnosis. The patients were followed by telephone from September to October in 2019, and the outcome was recorded. The primary outcome was all-cause death 28 days after discharge. The secondary outcomes were all-cause death in intensive care unit (ICU) and 2 years after discharge, and the length of ICU stay. The patients were divided into two groups according to prognosis of 28 days: the survival group and the death group. The clinical data of the two groups were compared. Multivariate Cox regression analysis was used to screen prognostic risk factors of 28 days in patients with SS. The receiver operating characteristic (ROC) curve was used to explore predictive value of liver function parameter SChE for 28-day prognosis of patients with SS. The patients were divided into two groups according to the levels of SChE: the low SChE group (SChE ≤ 4 000 U/L) and the normal SChE group (SChE > 4 000 U/L). Kaplan-Meier survival curves were used to compare the cumulative survival rates without endpoint event of patients with different SChE levels.
RESULTS: A total of 385 patients with SS were enrolled according to the inclusion and exclusion criteria, and a total of 356 patients were followed up successfully, with a follow-up rate of 92.5% (356/385). There were 142 survival patients and 214 death patients at 28 days, with a 28-day mortality rate of 60.1% (214/356). There were 116 survival patients and 240 death patients at 2 years, with a 2-year mortality rate of 67.4% (240/356). Compared with the 28-day survival group, the patients in the death group were older and had higher APACHE II score, partial hepatic and renal function parameters, higher level of blood lactate (Lac) and lower levels of white blood cell count (WBC), platelet count (PLT) and SChE with statistically significant differences. Multivariate Cox regression analysis showed that the age [relative risk (RR) = 1.444, 95% confidence interval (95%CI) was 1.090-1.914, P = 0.010], APACHE II score (RR = 2.249, 95%CI was 1.688-2.997, P = 0.000), SChE (RR = 1.469, 95%CI was 1.057-2.043, P = 0.022), and Lac (RR = 2.190, 95%CI was 1.636-2.931, P = 0.000) were independent risk factors for 28-day mortality of patients with SS. The ROC curve analysis showed that SChE had a weak prognostic value for 28-day prognosis of patients with SS [the area under ROC curve (AUC) was 0.574]. However, the combined predictive value of SChE, APACHE II score and Lac was greater than APACHE II score or Lac alone for prediction (AUC: 0.807 vs. 0.785, 0.697), with a sensitivity of 79.9% and a specificity of 68.5%. Compared with the normal SChE group (n = 88), the 28-day mortality of patients in the low SChE group (n = 268) was significantly increased [63.1% (169/268) vs. 51.1% (45/88), P < 0.05], but ICU mortality [59.7% (160/268) vs. 48.9% (43/88)], 2-year mortality [69.8% (187/268) vs. 60.2% (53/88)] or the length of ICU stay [days: 4 (2, 7) vs. 5 (2, 9)] between the two groups showed no statistical significance (all P > 0.05). Kaplan-Meier survival curve analysis showed that the cumulative survival rate without endpoint event of patients in the low SChE group was significantly lower than that in the normal SChE group (Log-Rank test: χ2 = 5.852, P = 0.016).
CONCLUSIONS: Increased risk of 28-day mortality in patients with SS whose SChE is below normal. The level of SChE is an independent risk factor for 28-day death in SS patients, and it is one of the indicators to evaluate the short-term prognosis of patients with SS.
参考来源
- Zhao R, Zhang X, Wang H, et al. [Value of serum cholinesterase in the prognosis of septic shock]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32148230. doi:10.3760/cma.j.cn121430-20191219-00008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。